AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39162825
Drug: Combined qPLR
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined qPLR < 4% and NPi ≤ 2 with NSE > 60 μg/L
Trial: 39162872
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + chemotherapy (SOX or CAPOX)
Trial: 39162872
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + chemotherapy (SOX or CAPOX)
Trial: 39163044
Drug: Maya mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maya mobile app-based cognitive behavioral therapy (CBT) intervention for 6 weeks with text message-based incentives (gain-framed, loss-framed, gain-social support)
Trial: 39163044
Drug: Maya mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maya mobile app-based cognitive behavioral therapy (CBT) intervention
Trial: 39163362
Drug: CRP-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-guided treatment
Trial: 39163591
Drug: uTECH+YMHP (SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: uTECH+YMHP (SMS text messages informed by ML algorithm + YMHP counseling)
Trial: 39163858
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) 4 g
Trial: 39163971
Drug: Maple syrup
RxNorm normalized name: MAPLE SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maple syrup
Trial: 39163971
Drug: Sucrose syrup
RxNorm normalized name: sucrose syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose syrup
Trial: 39163972
Drug: Total polyphenol
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total polyphenol intake (∼914 mg/1000 kcal/d)
Trial: 39164041
Drug: Secondary cytoreductive
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreductive surgery followed by platinum-based chemotherapy plus or minus bevacizumab
Trial: 39164041
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy plus or minus bevacizumab alone
Trial: 39164067
Drug: apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apremilast 30 mg two times per day
Trial: 39164407
Drug: Bosutinib (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib (starting dose: 500 mg QD)
Trial: 39164518
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor pathway inhibitors (ARPIs)
Trial: 39164613
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural injections (TEI)
Trial: 39164673
Drug: 10-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-valent pneumococcal conjugate vaccine (PCV10)
Trial: 39164808
Drug: 7-day vonoprazan-based
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 7-day vonoprazan-based triple therapy with high-dose amoxicillin (VAC-7)
Trial: 39164808
Drug: 14-day extended
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14-day extended sequential therapy (S-14)
Trial: 39164933
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) - 25 weekly sessions including behavioural activation, behaviour management, interventions for the caregiver, reminiscence, couples counselling, and cognitive restructuring
Trial: 39165373
Drug: Evening LAMA
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening LAMA administration
Trial: 39165373
Drug: Morning LAMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning LAMA administration
Trial: 39166425
Drug: SHR-2004 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-2004 (0.1, 0.3, or 1.0 mg/kg) administered intravenously (i.v.)
Trial: 39166425
Drug: SHR-2004 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-2004 (0.5, 1.0, 3.0, or 4.5 mg/kg) administered subcutaneously (s.c.)
Trial: 39166750
Drug: Higher hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher hepatic glucose production (HGP-insulin)
Trial: 39167148
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet of selvigaltin under fasted conditions
Trial: 39167148
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet of selvigaltin under fed conditions
Trial: 39167148
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule of selvigaltin under fasted conditions
Trial: 39167148
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments of selvigaltin (tablet and capsule)
Trial: 39167305
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel with AGS
Trial: 39167348
Drug: Venetoclax treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax treatment
Trial: 39167348
Drug: Venetoclax treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax treatment with concomitant rituximab
Trial: 39167348
Drug: Venetoclax treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax treatment with 1 prior line of therapy
Trial: 39167348
Drug: Venetoclax treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax treatment with ≥ 2 prior lines of therapy
Trial: 39167366
Drug: Zasocitinib 2
RxNorm normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zasocitinib 2 mg
Trial: 39167366
Drug: Zasocitinib 5
RxNorm normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zasocitinib 5 mg
Trial: 39167366
Drug: Zasocitinib 15
RxNorm normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zasocitinib 15 mg
Trial: 39167366
Drug: Zasocitinib 30
RxNorm normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zasocitinib 30 mg
Trial: 39167366
Drug: Zasocitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zasocitinib (all doses)
Trial: 39167421
Drug: CBD (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene)
Trial: 39167533
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous PTH (1-34) infusion
Trial: 39167741
Drug: Personalized chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized chemotherapy based on tumor marker decline
Trial: 39167748
Drug: Migraine frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine frequency less than monthly
Trial: 39167807
Drug: Belzutifan (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belzutifan (120 mg orally once daily)
Trial: 39168564
Drug: Olpasiran 75
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 75 mg Q12W
Trial: 39168564
Drug: Olpasiran 225
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 225 mg Q12W
Trial: 39169058
Drug: Immune killer
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immune killer cells (IKC) infusion weekly for 24 weeks
Trial: 39169058
Drug: Immune killer
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immune killer cells (IKC) infusion
Trial: 39169095
Drug: Invisalign treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisalign treatment with upper and lower aligners (average treatment time of 18 ± 6 months)
Trial: 39169298
Drug: 5-day postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day postoperative antibiotic therapy (piperacillin/tazobactam)
Trial: 39169349
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment group using the Dialogue Support
Trial: 39169349
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment group using the Dialogue Support
Trial: 39169353
Drug: Soymilk (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk (500 mL daily, 22 g soy protein, 17.2 g or 6.9 g/250 mL added sugars)
Trial: 39169699
Drug: PEERS® program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEERS® program (treatment group, n=10)
Trial: 39169827
Drug: DS-7011a (anti-TLR7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-7011a (anti-TLR7 monoclonal antibody) administered intravenously (IV) and subcutaneously (SC) in a 6:2 ratio against placebo.
Trial: 39169827
Drug: DS-7011a (anti-TLR7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-7011a (anti-TLR7 monoclonal antibody) administered IV and SC.
Trial: 39170110
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg esketamine + PCEA
Trial: 39170110
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg esketamine + PCIA
Trial: 39171074
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nonpharmacological interventions including a daily dose of both investigational products and dietary counseling on increasing dietary fiber.
Trial: 39171074
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of both investigational drugs only.
Trial: 39171394
Drug: Intravenous acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetazolamide
Trial: 39172479
Drug: Olaparib, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib, 300 mg by mouth twice daily until PSA doubling, clinical or radiographic progression, or unacceptable toxic effects.
Trial: 39172730
Drug: ARX517 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARX517 (a site-specific stable PSMA-targeted antibody-drug conjugate)
Trial: 39173075
Drug: TAK-003 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 vaccine (two doses administered 3 months apart)
Trial: 39173075
Drug: TAK-003 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 vaccine (baseline vaccination scenario)
Trial: 39173075
Drug: TAK-003 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 vaccine (extreme high scenario)
Trial: 39173088
Drug: CEE-alone (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE-alone (0.625 mg daily)
Trial: 39173088
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus MPA (0.625 mg CEE plus 2.5 mg MPA daily)
Trial: 39173175
Drug: Lumacaftor/Ivacaftor treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor/Ivacaftor treatment
Trial: 39173229
Drug: Plinabulin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plinabulin (30 mg/m²), nivolumab (1 mg/kg), ipilimumab (3 mg/kg)
Trial: 39173560
Drug: Pill counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill counts (PC)
Trial: 39173703
Drug: Preconception vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconception vitamin D status and bioavailability
Trial: 39174285
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care treatment for LTBI
Trial: 39174285
Drug: Secondary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary care treatment for LTBI
Trial: 39174449
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) plus progressive muscle relaxation (PMR) intervention
Trial: 39174542
Drug: Sintilimab (anti-PD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT), and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Trial: 39174857
Drug: Delayed-release form
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release form containing 1.9 mg melatonin, 10 mg zinc, and 200 mg lemon balm extract
Trial: 39174857
Drug: Delayed-release form
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release form
Trial: 39174958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 native implants)
Trial: 39175342
Drug: Day-2-group (warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-2-group (warfarin started on day 2 after CS)
Trial: 39175342
Drug: Day-5-group (warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-5-group (warfarin started on day 5 after CS)
Trial: 39175480
Drug: CHOPX (CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOPX (CHOP plus targeted agents)
Trial: 39175547
Drug: Fospropofol disodium
RxNorm normalized name: Fospropofol disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fospropofol disodium (6.5 mg/kg initial bolus, 1.6 mg/kg supplemental as needed)
Trial: 39175547
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg initial bolus, 0.5 mg/kg supplemental as needed)
Trial: 39176240
Drug: Add-on low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on low dose Astragalus membranaceus (AM) for 24 weeks
Trial: 39176240
Drug: Add-on high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on high dose Astragalus membranaceus (AM) for 24 weeks
Trial: 39176240
Drug: Add-on low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on low dose Astragalus membranaceus (AM)
Trial: 39176240
Drug: Add-on high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on high dose Astragalus membranaceus (AM)
Trial: 39176240
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (low dose AM, high dose AM, routine care)
Trial: 39178168
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy dressings (Prevena™ and PICO™)
Trial: 39179206
Drug: FIBCRO (sourdough-leavened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIBCRO (sourdough-leavened croissant enriched with dietary fibers, 4.8 g/100 g)
Trial: 39179206
Drug: CONCRO (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONCRO (control croissant, dietary fibers 1.3 g/100 g)
Trial: 39179207
Drug: Synbiotic (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic (400 mg/100 mL GOS and L. reuteri DSM 17938)
Trial: 39179255
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) including anti-PD-1 (79.3%), anti-PD-L1 (17.9%), combination of anti-PD-1 and anti-CTLA-4 (2.1%), anti-PD-1 with anti-VEGFR (0.7%)
Trial: 39179638
Drug: S-MDMA (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-MDMA (125 mg)
Trial: 39179638
Drug: R-MDMA (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-MDMA (125 mg and 250 mg)
Trial: 39179638
Drug: R-MDMA (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-MDMA (125 mg)
Trial: 39179638
Drug: R-MDMA (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-MDMA (250 mg)
Trial: 39179855
Drug: CyberRwanda facilitated
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyberRwanda facilitated arm (peer-led clubs plus tablet access)
Trial: 39179855
Drug: CyberRwanda self-service
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CyberRwanda self-service arm (self-guided access on tablets)
Trial: 39179863
Drug: Tislelizumab combined
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab combined with cisplatin and 5-fluorouracil (induction therapy)
Trial: 39180187
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with endocrine therapy (bicalutamide for 4 weeks and abiraterone for 2 years)
Trial: 39180325
Drug: PF-06425090 vaccine
RxNorm normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06425090 vaccine (3 doses at 0, 1, and 6 months)
Trial: 39180326
Drug: Fecal microbiota,
RxNorm normalized name: fecal microbiota, live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota, live-jslm (REBYOTA) administered rectally within 24-72h of antibiotic completion.
Trial: 39180326
Drug: Fecal microbiota,
RxNorm normalized name: fecal microbiota, live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota, live-jslm (REBYOTA) administered rectally.
Trial: 39181037
Drug: EPA/DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA supplementation (2.0 g daily for 10 weeks)
Trial: 39181037
Drug: HMB +
RxNorm normalized name: Hydroxymethylbutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB + EPA/DHA supplementation (3.0 g Ca-HMB daily for 10 weeks)
Trial: 39181206
Drug: Lutein/zeaxanthin (LZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein/zeaxanthin (LZ) intake (≥2 mg/day compared with <2)
Trial: 39181206
Drug: Higher intake
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher intake of ω-3 fatty acids (≥0.7 g/week compared with <0.7)
Trial: 39181422
Drug: Canakinumab (CAN)
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab (CAN) 3 mg/kg
Trial: 39182045
Drug: suPAR >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR > 5.1 ng/mL
Trial: 39182045
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of suPAR > 9.8 ng/mL, BMI < 29.3 kg/m2, PSI > 106.5
Trial: 39182315
Drug: Vaccine Declined
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine Declined
Trial: 39182330
Drug: Alirocumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab plus statin therapy
Trial: 39182487
Drug: IV thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV thrombolysis (IVT) in patients on oral anticoagulation
Trial: 39182487
Drug: IV thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV thrombolysis (IVT) in patients without oral anticoagulation
Trial: 39182655
Drug: Sirukumab 5
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 5 mg/kg IV on Day 1 plus standard of care
Trial: 39184998
Drug: AGuIX nanoparticles
RxNorm normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AGuIX nanoparticles (4 injections at 50, 75, and 100 mg/kg) with radiotherapy (RT 60 Gy) and concomitant/adjuvant temozolomide (TMZ)
Trial: 39184998
Drug: AGuIX nanoparticles
RxNorm normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AGuIX nanoparticles (100 mg/kg)
Trial: 39185596
Drug: SLFN11-positive tumors
RxNorm normalized name: HUMAN BREAST TUMOR CELL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLFN11-positive tumors (e.g., mesotheliomas, clear cell renal cell carcinomas, small cell lung cancers, squamous cell carcinomas of the tonsil and larynx, ovarian serous carcinomas)
Trial: 39185596
Drug: SLFN11-negative tumors
RxNorm normalized name: HUMAN BREAST TUMOR CELL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLFN11-negative tumors (e.g., hepatocellular, prostatic, colorectal, breast cancers)
Trial: 39186143
Drug: Add-on dupilumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on dupilumab therapy